Rapport Therapeutics (RAPP) News Today $10.82 -0.30 (-2.70%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$10.82 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Rapport Therapeutics to Host 2025 Investor and Analyst DayMay 21, 2025 | globenewswire.comCompanies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In GrowthMay 17, 2025 | finance.yahoo.comCrestline Management LP Acquires New Stake in Rapport Therapeutics (NASDAQ:RAPP)Crestline Management LP bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 27,496 shares of the company's stock, valued at aMay 13, 2025 | marketbeat.comRapport Therapeutics Reports Q1 2025 Financial ResultsMay 10, 2025 | tipranks.comOptimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 DevelopmentsMay 8, 2025 | tipranks.comPromising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.May 8, 2025 | tipranks.comRapport Therapeutics Reports First Quarter 2025 Financials and Provides Business UpdateMay 8, 2025 | globenewswire.comInductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI PlatformMay 7, 2025 | finance.yahoo.comRapport Therapeutics (NASDAQ:RAPP) Stock Position Boosted by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD raised its stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,143,384 shares of the company's stock aMay 4, 2025 | marketbeat.comMise à disposition du rapport financier annuel 2024April 30, 2025 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Shares Sold by T. Rowe Price Investment Management Inc.T. Rowe Price Investment Management Inc. reduced its holdings in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,636,931 shares of the company'April 29, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Short Interest UpdateRapport Therapeutics (NASDAQ:RAPP - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,800,000 shares, a growth of 21.2% from the March 15th total of 2,310,000 shares. Based on an average trading volume of 219,400 shares, the days-to-cover ratio is presently 12.8 days. Currently, 16.1% of the shares of the company are short sold.April 22, 2025 | marketbeat.comRapport Therapeutics to Participate in Upcoming Investor ConferencesApril 22, 2025 | globenewswire.comTrv Gp V LLC Invests $126.58 Million in Rapport Therapeutics (NASDAQ:RAPP)Trv Gp V LLC acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 7,135,233 shares of the company's stock, valued at approximately $126,579,000. Rapport Therapeutics accounts forApril 22, 2025 | marketbeat.comTrv Gp Vi LLC Invests $17.19 Million in Rapport Therapeutics (NASDAQ:RAPP)Trv Gp Vi LLC acquired a new position in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 969,218 shares of the company's stock, valued at approApril 22, 2025 | marketbeat.comMeloni and Trump: An Oval Office Meeting With Rapport and BanterApril 18, 2025 | nytimes.com48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges BankNorges Bank purchased a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 48,452 shares of the company's stock, valued at approximately $860,000April 14, 2025 | marketbeat.comJMP Securities Initiates Coverage on Rapport Therapeutics (NASDAQ:RAPP)JMP Securities started coverage on shares of Rapport Therapeutics in a research report on Tuesday. They set a "market outperform" rating and a $28.00 price target on the stock.April 10, 2025 | marketbeat.comCitizens Jmp Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP)Citizens Jmp began coverage on Rapport Therapeutics in a research report on Tuesday. They set a "mkt outperform" rating on the stock.April 10, 2025 | marketbeat.comRapport Therapeutics initiated with an Outperform at Citizens JMPApril 9, 2025 | markets.businessinsider.comBuy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS DisordersApril 9, 2025 | tipranks.comJMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform RecommendationApril 9, 2025 | msn.comRapport Therapeutics (NASDAQ:RAPP) Short Interest Up 27.6% in MarchRapport Therapeutics (NASDAQ:RAPP - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 2,310,000 shares, a growth of 27.6% from the February 28th total of 1,810,000 shares. Approximately 13.3% of the company's shares are short sold. Based on an average daily trading volume, of 202,200 shares, the short-interest ratio is presently 11.4 days.April 2, 2025 | marketbeat.comRapport Therapeutics: Too Early To Be InterestingMarch 31, 2025 | seekingalpha.comCrédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024March 27, 2025 | globenewswire.comRapport Therapeutics to present data at 2025 AAN meetingMarch 22, 2025 | markets.businessinsider.comBpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCEMarch 21, 2025 | globenewswire.comRapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual MeetingMarch 21, 2025 | globenewswire.comPositive Signs As Multiple Insiders Buy Rapport Therapeutics StockMarch 15, 2025 | finance.yahoo.comInsider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of SharesMarch 15, 2025 | finance.yahoo.comWendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockRapport Therapeutics (NASDAQ:RAPP - Get Free Report) Director Wendy B. Young acquired 6,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were acquired at an average price of $10.21 per share, for a total transaction of $61,260.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.March 14, 2025 | marketbeat.comInsider Buying: Rapport Therapeutics (NASDAQ:RAPP) CFO Purchases 9,900 Shares of StockRapport Therapeutics (NASDAQ:RAPP - Get Free Report) CFO Troy A. Ignelzi acquired 9,900 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the purchase, the chief financial officer now directly owns 9,900 shares of the company's stock, valued at $99,990. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 14, 2025 | marketbeat.comWendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMarch 14, 2025 | insidertrades.comCorrection: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13, 2025 | globenewswire.comCorrection: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13, 2025 | globenewswire.comRapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | finanznachrichten.deMise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13, 2025 | globenewswire.comRapport Therapeutics sees cash runway through 2026March 12, 2025 | markets.businessinsider.comRapport Therapeutics Reports 2024 Financial Results and ProgressMarch 12, 2025 | tipranks.comRapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last yearMarch 11, 2025 | markets.businessinsider.comRapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 11, 2025 | gurufocus.comRapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 11, 2025 | globenewswire.comRapport Therapeutics Inc trading resumesMarch 4, 2025 | markets.businessinsider.comRapport Therapeutics Inc trading halted, volatility trading pauseMarch 4, 2025 | markets.businessinsider.comRapport Therapeutics Appoints New CMO Amid Phase 2a UpdatesMarch 3, 2025 | tipranks.comRapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine DevelopmentMarch 3, 2025 | globenewswire.comRapport Therapeutics to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comRapport Therapeutics (RAPP) Expected to Announce Earnings on ThursdayRapport Therapeutics (NASDAQ:RAPP) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 8.5% - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5% - Here's WhyFebruary 19, 2025 | marketbeat.comRapport Therapeutics, Inc. (RAPP)February 15, 2025 | ca.finance.yahoo.com Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPP Media Mentions By Week RAPP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPP News Sentiment▼0.000.75▲Average Medical News Sentiment RAPP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPP Articles This Week▼12▲RAPP Articles Average Week Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EVO News Today IMCR News Today MESO News Today VERA News Today DYN News Today GPCR News Today ADPT News Today ANIP News Today SPRY News Today CALT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPP) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
